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Methods: In an open, uncontrolled study 30 infants and 30 children received
without prior screening vaccine doses intramuscularly at baseline (BL) and at
month 12. Safety was assessed for 4 days after the immunisations. Serum
anti-HAV antibodies were determined by EIA (ENZYMUN Boehringer)
at BL, on day 29, and at months 12 and 13.
Results: Fourteen infants had maternal antibodies (Mat-Ab) at BL (20-580
mIU/ml) and on day 29; 16 were seronegative « 20 mlU/ml) at BL.
Seroprotection (> 1= 20 mlUIml) was achieved by 1()()% of seronegative
infants and all children on day 29 (GMT: 169 and 126 mIU/ml). All infants
and children remained seroprotected until month 12 (GMT: 134 and 108
mIU/ml) and responded strongly to the booster (GMT: 2268 and 2541 mlU1
ml). The infants whithout Mat-Ab at BL had higher titers at month 12
(GMT: 180 vs 102 mlUIml) and responded significantly better to the booster
(GMT: 4341 vs 1185 mlU/ml). Vaccination was well tolerated.
Conclusions: Infants and children can safely and successfully be vaccinated
against hepatitis A from age 6 months on. Despite a negative interference by
Mat-Ab on the antibody titers achieved, the marked booster reponse
suggests that the infants were primed regardless of the presence of Mat-Ab.
P:15 - Vaccines
IWeP284!lmmunogenicity and tolerability of a preservative-
free influenza vacdne
A. Banzhoff, C. Schwenke, M. Broker
Chirotl Vaccines, Chiron Behring GmbH & Co, Marburg, Germany
Objectives: Recently, US and European regulatory authorities and vaccine
manufacturers have agreed to remove organomercuric preservatives from
vaccines based on a new benefit/risk evaluation. We have therefore inves-
tigated the immunogenicity and tolerability of the novel preservative-free
inactivated influenza vaccine Begrivaci'.'.
Methods: In a prospective study, carried out in autumn 1998, efficacy was
evaluated by the increase of influenza virus antibody titres from baseline to
21 days after vaccination. A total of 120 subjects were enrolled: 61 aged 18-
59 (adults) and 59 aged $;60 years (elderly). The safety variables included
local and systemic reactions and all adverse events. The antibody titres were
determined by hemagglutinin-inhibition assay.
Results: All three of the European efficacy requirements for influenza
vaccines, namely the seroconversion rate, the protection rate and the
conv"rsion factor. w"re met by the new preservative-free vaccine described
in this report for the thrcc stains. The mean geometric increase and the
proportion of vaccination responders were greater in patients of the adult
group than in the elderly. 53% ofthe subjects reponed local reactions such as
pain, erythema and induration, or systemic reactions such as headache and
fatigue.
Condusions: The present study demonstrates that the novel preservative-
free influenza vaccine is efficacious, retains its good tolerability profile and is
in accordance with the European requirements for influenza vaccines. This
new preservative-free influenza vaccine may contribute to increase the
compliance and lead to a higher vaccination rate.
IWeP28S1 safety and immunogenicity of a subunit influenza
vacdne
M. Minutello', A. Gruppioni2, I. Bastianoni', E. Montomole, R.
Gasparini3 , A. Podda
'Chiron Vaaines, Siena; 2ASL Vignola, Modena; JInst. ofHygiene, Univ. of
Siena, Italy
Objectives: To evaluate safety and immunogenicity of a subunit influenza
vaccine (formulation 1999-2000) in a population of young and elderly
people. .
Methods: Fifty-two adult subjects ($;60 years) and fifty-five elderly subjects
(> 60 years) received one dose of the Chiton subunit influenza vaccine
(AGRIPPAL SI™) and were monitored for reactogenicity through day 6
post-immunisation and safety during the entire 21 day study period.
Single Radial Haemolysis (SRH) assay was used to test the immunogeni-
city. The criteria were those recommended by the European Community
Committee,
Results: The immunogenicity results are reponed in the following table:
A/(H3N2) A/(HINI) B
Requirement n/N % n/N % n/N %
Adults N = 52
Seroconversion
rate > 40% 30/52 57.7 29/52 55.8 33/52 63.5
Mean GMT
increase > 2.5 3.353 3.408 3.130
SeroprOle,:tion
44/52 84.6rate > 70% 37/52 7\.2 41/52 78.8
Eldcrly N = 55
Scroronvcnion
rate > 30% 24/55 43.6 19/55 34.5 34/55 61.2
Mean GMT
increase >2 2.603 2.325 2.960
Seroprotection
rate > 600/0 36/55 65.5 40/55 72.2 44/55 80.0
Conclusions: Agrippal SIS was demonstrated to be safe and highly immu-
nogenic. AcruaIly, all thc European Community Committee immunogell.i-
city criteria were met for the thrcc influenza strains.
IWeP28611naeased Immunogenicity of the MF59-adjuvanted
influenza vacdne
M. Minutellol , T. Pozzi2, F. Senatorel , R. Gasparini2, A. Poddal
Chiron Vaccilles, Clinical Research, 53100 Siena, Ild/y
Objectives: To compare safety and immunogenicity of the MF59-adju-
vanted influenza vaccine (FLUADS ) to a conventional influenza subunit
vaccine (AGRIPPAL SIS) in elderly subjects.
Methods: Three-hundred and eight outpatient elderly subjects (~65 years)
were randomly assigned to receive one dose ofFLUAD8 or AGRIPPAL
SIS and were monitored for any reaction and other adverse events through
day 6 post-immunisation and any medical problem during the entire study
period. A blood draw for immunogenicity was obtained at day 0 and 28 days
after immunisation.
Results: No safety differences between the study vaccines were found with
the exception of a higher percen~eof mild pain at the injection site in
subjects immunised with FLUAD . lmmunogenicity results are reported
below:
Hlvniahl~ FLUAD AGRIPPALSI
Antigen (n = 192) (n = 99)
Geometric mean titre B 102*** 70
(GMT) A/HINI 191 167
A/H3N2 103*** 55
% ofsubjects with B 35* 27
~ fourfold increase A/HINI 20** 11
A/H3N2 52***29
% ofsubjects with B 54*** 35
titre ~ 1/160 AjHINI 88 85
A/H3N2 51*** 34
*p :s; 0.05: **p :s; 0.01: ***P :s; 0.001
Condusions: Both study vaccines were shown to be safe. The adjuvanted
vaccine was clearly more immunogenic than the conventional influenza
vaccine; for this reason it should be preferred for immunisation of elderly
people, who have a higher risk of developing influenza and its related
complications.
IWeP281! Appropriate needle length for Influenza
immunization: Fat pad thickness and local adverse events In an
older population
M. Neisen. G. Poland, R. Jacobson, R. Vierkant, D. Brakke, G. Chatfield
Mayo Vaccine Research Group, Mayo Clitlic, Rochrster, MI, United States
Background: For adult influenza immunization, intramuscular injection is
recommended. Whether a 16 mm needle adequately reaches muscle in older
adults is unknown. The purpose of this study was to gather data on deltoid
fat pad thickness and to compare side dfects as a function of vaccine
deposition site.
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Methods: 133 adults, ages 50 to 88 years, were randomized to receive 1999-
2000 trivalent influenza vaccine intentionally into the deltoid muscle or into
the deltoid fat pad. Sixty-six participants randomly underwent ultrasono-
graphy ofbilateral deltoid regions prior to immunization to measure deltoid
fat pad thickness. A blinded interviewer administered a side effect survey to
each participant 2-3 days after vaccination.
Results: The mean skin-to-muscle thickness for men and women was
different (9.9 mm [range 6.7 mm to 14.0 mm) vs 11.8 mm [range 6.9 mm
to 24.3 mm), p = 0.01). Based on ultrasound, '116 mm needle would not
have adequately penetrated muscle in 26% of the men and 51 % of the
women. This difference was statistically significant (p = 0.03). A 16 mm
needle would not have adequately penetrated muscle in 48% of subjects
below age 65 as contrasted to 27% greater than 65. A 25 mm needle would
have adequately penetrated muscle in all but 3% of those subjects who
underwent ultrasonography. Those receiving intentional fat pad injections
reported more frequent redness or swelling following immunization than
those receiving intramuscular injections (34% vs 5%, P < 0.(01).
Conclusion: To ensure adequate muscle penetration and to minimize red-
ness and swelling, a needle length of 25 mm or longer should be used for
adult influenza immunization.
[WeJi2iii] How to promote immunisation against influenza?
P. Hovier1, M. Bouvier Gallacchi2, L. Loutan'
1Travel and migration medicine unit, Department ofcommunity medicine,
Geneva University Hospitals; 2General internal medicine practitionner, Melide,
Switzerland
Objectives: To identify the characteristics oflow use ofinfluenza vaccine in
patients over 15 years consulting a primary care practitioners in Switzerland.
Methods: Data were collected using self-administered questionnaires,
according to a two-stage cluster sampling. First, 178 general practitioners
were identified from a registry ofprimary care physicians, who volunteered
to participate in clinical research projects. Second, these physicians were
asked to deliver a questionnaire to 20 consecutive patients coming to their
practice. The patients were asked whether they had received a vaccine
against influenza in the last 12 months. Additional items asked for the
opinion of the patient about influenza vaccine and immunisation in general,
and whether their physician had proposed them to be immunised. Respon-
dents over 65 years or with co-morbidities were considered as potential
vaccine recipients. Logistic regression was used to study the effects of
patient's opinion and physician'S behaviour on low use ofinfluenza vaccine.
Results: 124 physicians and 2042 patients participated in the survey. 638
were potential vaccine recipients for influenza. Not having received the
advice to be immunised and considering that immunisation against influenza
is useless were strongly and independently associated with lower self-
reported use of influenza immunisation (both P < 0.(01). Promotion
through the mass media resulted in increased awareness of the physicians
and more favourable opinion of the patients.
Conclusion: These results stress the importance ofmulti-level interventions
when implementing public health policies in order to improve vaccine use.
For influenza, such policies should target both the physicians and potential
vaccine recipients.
IWeP289! Long-term immunogenicity after two doses of a
virosome hepatitis A vacdne
P. Bovier!, L. Loutan', T. Farinelli', C. Herzog2
1Travel and migration medicine unit, Department ofcommunity medicine,
Geneva University Hospitals; 2Swiss Serum and Vaccine Institute Berne,
SUlitzerla"d
objectives: To determine the persistence of detectable antibodies against
hepatitis A virus after two doses of virosome hepatitis A vaccine (Epaxal),
administered as a single vaccine or with other immunisations.
Methods: A prospective cohort study including 153 volunteers was set-up.
A first group of 104 volunteers received only the hepatitis A vaccine, while
another group of 49 volunteers received the hepatitis A vaccine, as well as
other immunisations recommended for a stay in tropical countries. All
volunteers were followed-up for 6 years (M24, M36, M48, M60, M72 and
M84), following the second dose of the hepatitis A vaccine. Antibody titres
were checked every year, using a commercial ELISA test (Enzymmun-Test
Anti-HAY). Titres over 10 mlU/ml were considered as positive.
Results: GMT were 824, 595, 591, 482, 469 and 393 mlU/ml for 122, 104,
102, li9, 52, and 70 vaccinees respectively. Titres were statistically lower in
male volunteers, but no significant difference was observed between the two
study groups. The seroconversion rate remained over 100% until M72. At
M84, two male volunteers had titres below 10 mlU/ml, resulting in a
seroconversion rate of97%. Based on an "extrapolation model ofantibody
decay", the median persistance time ofdetectable antibody was estimated to
last over 20 years for both groups.
Conclusion: The immunity conferred after two doses of the virosome
hepatitis A vaccine is excellent, when administered as a single vaccine or
with other immunisatiom. The duration ofthis protection is expected to last
many years.
IWeP2901 Long.tenn follow-up of patients with chronic renal
failure vacdnated against hepatitis B
L. ROZllovsk/, I. Lochman2, I. Onagovat , A. SulakovaI
,Department of Infectious Diseases; 2Department of Immunology and
Allergology, Ostrava, Czech Republic
Objectives: Anti-HBs antibodies response and breakthrough infections
were investigated in 414 patients with chronic renal failure (81 pre-dialysis.
272 dialysis patients, iii patients with renal transplantation) vaccinated
against hepatitis B.
Methods: Active immunisation against hepatitis B was commenced in 1988
y. The vaccination schedule was 0, 1, 2 months for dialysis patients and
patients with renal transplantation and 0, I, 6 moths for pre-dialysis patients.
Plasma-derived or since 1990 recombinant vaccine were administered
intramuscularly, each vaccine contained 40 J.lg of HBsAg, but for pre-
dialysis patients only 20 J.lg till 1998 y. The patients without protective anti-
HBs level after vaccination were twice re-vaccinated.
Results: Anti-HBs antibodies after vaccination were investigated in 232
patients. Protective anti-HBs level were observed in 34.1%, 51.7% and
55.6% patients after third, fourth and fifth vaccine.
The new HBsAg positive status was proved in 28 dialysis patients, the
latest one was observed in 1994. Most of patients suffered by hepatitis B.
The new appearance ofanti-HBc without HBsAg presence was proved in
8 patients.
Condusions: Vaccination of patients with chronic renal failure is not
satisfactory, but long-term vaccination of them considerably reduces hepa-
titis B incidence.
IWeP291I The reason for rejection of hepatitis Bvacdnation
by medical personnel
V. S. Tokmakov, A. V. Smirnov, P. I. Ogarkov
Military Medical Academy, St. Petersburg, Russian Federation
Objectives: Medical personnel very often rejects hepatitis B vaccination.
The goal of the study is to determine the frequency and reason for this
phenomenon in the wake ofactual reactivity of the corresponding vaccine
and its danger for the human health.
Methods: Anonymous questioinnaire of the medical personnel in a multi-
purpose military medical establishment along with assessment of the
hepatitis B vaccine reactivity in the vaccinated were used.
Results: During the vaccination campaign in 1997-1998 52% of the
questioned rejected to be vaccinated. Among the reason for it there were
fear of some allergic reactions (34%), doubt about the effectiveness of the
vaccine (39%), uncertainty, in its safety for their health (14%), etc.
During the next vaccination campaign in 1999-2000 before the first
injection of the vaccine, explanatory work was carried on. Only 28.2% of
medical personnel rejected the vaccination (1.8 times less than in previous
campaign).
The study of the vaccinated revealed the reaction of the injection in 1.1 %
of cases: local reactions (redness and ache for 2 days) in 0.3%; general
reactions (fatique, headache, nausea for the 1-st day) in 0.3%; transitory
subfebrile body temperature in 0.5%.
Conclusions: reactivity of the hepatitis B vaccine is very low and does no
substantial harm on human health. The level of the benefit acknowledge-
ment of the vaccination among the medical personnel should be supported
by the proper medical information.
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IWeP292I Partially purified antigens of Bordetella Pertussis
S. Seatovic. D. Prekajski. G. Dakic. M.Jovicic. M. Vignjevic. K.
Mihailovic
Institute Torlak, Belgrade, Yugoslavia
Objectives: To develop a method for purification of major antigens of
Bordetella Pertussis.
Methods: Pertussis toxin (PT) and Filamentous hemaglutinin (FHA) are
major antigens of Bordetella Pertussis and important component of an
acellular pertussis vaccine against whooping caught. In this study we used
Tohama strain. phase I. The bacteria were grown in Cohen-Wheeler
mcdium at 36°C for 48h. The culture broth was concentrated using a 10
kD MW cut-offmembrane ofSARTOCON II system. After adjustment to
pH 3.80. the fermentation broth was stored at 4°C for 72h. Suspension of
bacteria was centrifuged l.sh at 2000 rpm. Supernatant was discarded ;md
pellet was extracted by extraction buffer (0.050 M TRIS-HCl. 1.000 M
NaC!. 3.000 M urea, 0.005 M EDTA, pH 8.00) and stored at 4°C for 24h.
Suspension was centrifuged l.Oh at 11000 rpm. Supernatant was collected
and extraction was repeated three times. Collected extract was dialyzed
against 0.010 M phosphate buffer. pH 8.00. This crude extract was applied to
hydroxiylapatite column on the BioPilot chromatographic system. equili-
brated by the same buffer.
Results: By use of the different phosphate buffer. PT and FHA were eluted
from hydroxiylapatite column. The purity of the isolated PT and FHA was
examined by SDS PAGE, immunoelctrophoresis and FPLC.
Conclusions: Using the described procedure. it is possible to purified FHA
and partially purified PT.
IWeP293!ln vitro phagocytosis of Bordetella pertussis after
opsonization with immune sera
P. Stefanelli!, R. Ippoliti2, C. Faziol • P. Mastrantonio
t Isti/l4to Superiore di Sanita', Rome; zUniversity of Rome, Italy"La
Sapienza"
Objectives: Bordetella pertussis, the human pathogen of whooping cough,
has shown to have invasive cell behaviour in vivo and in vitro.
In this study, serum opsonic capacity against B. pertussis was assessed using
sera from vaccinated children who participated in the Italian clinical trial for
the efficacy of acellular pertussis vaccines.
Methods: THPI human monocytes (ATCC T1B202). was incubated for 1 h
at 37°C. with 4',6-Diamino-2-Phenylindole (DAPI)-labeled B. pertussis 338
after opsonization with heat inactivated sera. Wheat Germ Agglutinin
TexasRed-X-conjugate was used to mark THPI cell membranes. Phago-
cyted bacteria were counted by direct observation with fluorescence video
microscopy and analysed with NIH-IMAGE Programm. Bacterial survival
was determined by plating and counting on Bordet Gengou agar.
Results: The results showed that without opsonization with immune sera
the number ofbacteria per monocyte amounted to 3.3 ± 1.5. with 49.5% of
cells infected. After opsonization with immune sera from children vacci-
nated with acellular pertussis vaccines. about 4.5 ± 2 bacteria were located
intracellularly, with 62.8% ofinfected monocytes. Fewer opsonized bacteria
with immune sera from vaccinees with the whole-cell vaccine, were
phagocyted. with only 38% ofinfected monocytes. B. pertussis PRN variant
strains. with different mutations in the RGD region, isolated from cases
during the trial. showed similar results obtained with B. pertussis 338.
Condusions: Sera from children vaccinated with acellular pertussis vaccines
with high efficacy were more efficient in facilitating phagocytosis than sera
obtained from children vaccinated with a whole-cell vaccine who showed a
very scarce efficacy.
IWeP294IImmune responses to Bordetella pertussis in
children with history of pertussis and in recipients of acellular
pertussis vaccine
C. M. Ausiello', R. Lande!, F. Urbani'. B. di Carlo', P. Stefanelli', S.
Salmaso.2, P. Mastrantonio1, A. Cassone!
'Dept. Bacteriology and Medical Mycology; zEpidemiology and Biostatistics,
Istiruro Superiore di Sal, ita, Rome, Italy
Objectives: To assess the persistence of immunity in pertussis and pertussis
vaccines, CMI and antibody responses were studied in 4-6 years old
recipients of primary vaccination with tricomponent acellular pertussis
(aP) vaccine and in unvaccinated children with history ofpertussis infection.
Unvaccinated, pertussis-unaffected children severed as controls.
Methods: CMI was assessed as lymphocyte proliferation and as cytokine
(IFN-")' and IL-5) determination by ELISA upon lymphocyte stimulation of
B. pertussis antigens. Seropositivity to pertussis antigens was measured with
standardized ELISA technique.
Results: Selective dominance of seropositivity to pertussis toxin (PT) was
detected in children with history of pertussis, whereas CMI to PT was the
dominant feature of vaccine recipients. Ab or CMI responses against
pertactin and filamentous hemagglutinin were of modest usefulness to
discriminate among the groups ofchildren in study. Type 1 cytokine profile
was detected in B. pertussis antigen activated PBMC in children with history
ofpertussis; conversely only a predominance oftype 1 cytokine profile (high
IFN-'"( and low IL-5 production) was detected in aP vaccine recipients.
Conclusions: Years after disease or vaccination, the humoral or cellular
nature of anti-PT response, was the main factor discriminating between
individual with history of pertussis infection and long-lasting protected aP
recipients. Possibly, the persistence ofCM! and protection is not only merit
of the vaccination but incorporates also the natural boosters due to the high
rate of exposure to B. pertussis in Italy.
IWeP29SII50lation and characterization of a low molecular
weight protein of Haemophilus influenzae
L. Estevez'. A. Callis'. P. Nunez2
IIntitute Finlay; ZBiological Researching Center Havana, Cuba
Objectives: Isolation of protein P6 from two autochthonous Haemophilus
infIuenzae (Hi) strains. Identification. immunological evaluation in mice and
evaluation of circulating antibodies in the serum from a patient with
meningitis caused by Hi type b (Hib).
Methods: Strain Hib 1 am/90 and strain 159 ofnon tipable Hi (NTHi) were
used. Outer membrane proteins (OMP) of Hib and NTH! isolates were
prepared using the modified Barenkamp method. The protein P6 from
strains 1 am/90 and 159 were isolated by Y;mg Ping and Murphy modified
procedures. P6 and OMP preparations were electrophoretically resolved
using the modified Laemmli method. By immunoblot the proteins faced a
monoclonal antibody (Mab) anti-P6 and serum from a patient recovered of
Hib meningitis. Sera extracted from immunized Balblc mice, with the P6
from Hib. were evaluated by Elisa.
Results: The P6 antigenic structure was recognized by the MAb in OMP
extracts from both evaluated strains and in the individual proteins. When the
human serum was applied in the immunoblot assay, evident delicate bands
were on the OMP extracts between the 35.3 and 49.5 kDa, and a more
intense band below the 20.5 kDa in all protein samples. P6 is immunogenic.
Conclusions: The 16 kDa isolated protein was P6. The P6 antigenic
structure is conserved in both autochthonous strains. P6 is an important
immunogen for humans and stands out of the rest of the OMP and the P6
isolated in the laboratory is immunogenic in Balblc mice.
IWeP296I Safety and immunogenicity of three Haemophilus
influenzae type Bconjugate vacdnes
G. Kanra', S. Viviani2• K. Yurdakok l , E. Ozmert', A. Anemona2, S.
Yal~n, O. Demiralp3. A. Kara ' , B. Cengjz!. B. Mutlu4, A. Poddl
I Department ofPediatric Itifectious Diseases, Medical Faculty, Hacceltepe
University, Ankara, Turkey; zMedical Dzartment, Chiron Vaccines, Siena,
Italy; JGiilveren Health Center, Ankara; Berk 114f lth, Ankara, Turkey
Objectives: To compare two Hib CRMl97-conjugate vaccines containing
Aluminum phosphate. ALP04. and Aluminum hydroxide, A1(OH)3. as
adjuvant to HBOC vaccine.
Methods: A total of 519 healthy 2 months old infants were enrolled and
randomized (2:2:1 ratio) to receive at 2. 4. 6 months ofage either HiblAlP04
vaccine. or HiblAI(OH)3 vaccine or HBOC vaccine. An active surveillance
for post-immunization reactions was performed on the 2nd and 7th day and
adverse events were collected up to 30 days after the third immunization. A
blood sample was obtained before and at 1 month after primary immuniza-
tion.
Results: Post-injection reactions were mild and similar among vaccine
groups. No related serious adverse events following any immunization
were reported. After three doses, all subjects in both Hib adjuv;mted vaccine
groups and 98% in the HBOC group had anti-PRP antibody level ~ 0.15
#Jg/mL. Ninety-three percent ofsubjects in Hib/AIP04 vaccine group. 91 %
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in Hib/Al(OH)3 group and 83% in HBOC group achieved anti-PRP
antibody level ~ 1 I-'g/mL. Anti-PRP GMTs in the three groups, after the
third immunization, were 9.91ttg/mL, 8.4 and 5.24 respectively
Conclusions: The presence of Aluminum adjuvants in the investigated Hib
CRM197-conjugate vaccines does not affect the safety profile, while
improve immunogenicity, as compared with HBOC vaccine.
IWeP297I Use of pneumococcus vaccine in the military
S. D.]ogolev, P.1. Ogarkov, S. A. Romanchuk
Military Medical Academy, St. Petersburg, Russian Federation
Objective: to evaluate the epidemiological efficiency, antigen activity and
reactogenicity ofpneumococcus vaccine in its application in military groups
with high risk of pneumonia development.
Methods: In the militaty training unit where the reinforcement takes place
every half-year in May and November and high incidence ofpneumonia is
registered annually, the vaccination with pneumococcal vaccine "Pneuma-
23" has been performed in December. 100 recruits at the age ofl8-20 were
vaccinated. Vaccine has been introduced intramusculary in the single dose of
0.5 m!' The control group consisted of 145 servicemen, who were in the
analogous conditions. For the investigation ofantigen activity ofthe vaccine
3-fold blood collection in tentative and control groups has been performed
before vaccination and within 1 and 4 months after vaccination.
Results: During the first month alter vaccination the level of acute respira-
tory disease (ARD) incidence in the 1.51 times less, acute bronchitis - 2.05,
pneumonia - 1.37 less than in the control group. During 2-5 months alter
vaccination the incidence ofARD among the vaccinated appeared to be 2.24
times less (t = 2.8; P < 0.01), acute bronchitis -12.97 (t = 3.58; P < 0.001),
and pneumonia - 6.14 (t = 3.36; P < 0.001) less than in the unvaccinated.
Thus vaccine fully manifests its protective features alter 3-4 weeks necessary
for the postvaccine immunity production and continue to retain them at
least for 5 months (investigation period). The postvaccination reactions were
not revealed. The analyses of serum by an indirect immunofluorescence
reaction with pneumococcus antigens revealed the significant increase of
pneumococcal antibodies in the vaccinated and their preservation during the
whole period of study.
Condusions: The pneumococcal vaccine "Pneuma-23" used in the military
appeared to be rather efficient with poor reactogenicity and possessed the
high antigen activity.
IWeP29SIIntrajejunai immunization of rabbits by E. coli-CFAlI
antigen combined with V. chole,.". toxin B encapsulated In
Iiposomes
V. F. Dima, R. Palade, P. lonescu, S. V. Dima l
Canracuzino Institute, Bucharest, Romania; 'Centro Medico-Chirurgico S.I.S
Hahnemann, Rome, Italy
Objectives: The purpose of this study was to evaluate the potential ofE. coli
o78:K80:Hl1 - colonization factor antigen (CFA/I) combined with Vibrio
cholerae toxin B (CTB) encapsulated in liposomes to induce humoral and
mucosal immune response.
Methods: Groups of young rabbits were intrajejunally immunized by
surgical methods with liposomes containing CFA/I (ISO I'g/dose) and
CTB (SO I'g/dose). The results show that intrajejunal immunization with
liposomes containing CFA/I and CTB antigens were protective against oral
challenge with 1.5 x 1010 E. coli 078:K80:H11 cells. The therapy promoted
marked immunity ofE. coli-CFA/I antigen as shown by humoral (lgA, IgG)
and mucosal cell-mediated immunity as well as by bacteriological and
histopathological findings. The CFA/I or CTB alone were less effective in
inducing immune response.
Condusions: These results suggested that liposomes containing CFA/I and
CTB antigens induced higher humoral and intestinal cytotoxic T-Iympha-
cyte responses as well as marked mucosal immunoadjuvant activity.
IWeP299! A new vaccine for immunological control of
toxoplasmosis
I. M. Nabih
National Research Centre, Dokki, Cairo, Egypt
Toxoplasmosis is an infectious disease caused by a protozoan parasite. It
forms a health problem since it infects animals associated with man such as
house pets. Sometimes, it is transfered from mother to fetus, causing serious
damage or even death of the child. Control of the disease by pure chemical
means is still lacking, since damage may still occur before treatment is
initiated. Besides, the parasite may show drug resistance. This new concept is
based upon immunological control of the parasite through the chemical
madification of its antigens. Reaction of the parasite cysts, with certain
chemical agents structurally related to the cyclohexenothiaxanthonc group,
with highly electrostatic character that were synthesized upon rational bases
to obtain chemically modified parasite antigens. Spectrophotometric studies
had shown the full uptake of the applied chemical agent in standardized
dilution upon incubation with the cysts for a period for 48 hours at 38°C.
The chemically pretreated cysts when given subcutaenously to host, mice,
had shown to give protection against infection by the parasite. Further the
same cured any preexisting infection when given by the same route to mice
already contracting the disease.
By this lead of madifieation the parasite antigens by chemical means, a
new vaccine of both protective and immunotherapeutic effect can be
obtained.
IWeP300IEect of small ruminant vaccination on the incidence
of human brucellosis in Tunisia
N. Bouzouaya, H. Bouzghaya
CHU Fat/ouma Bourguiba, Infectious Diseases, Monastir, Tunisia
Brucellosis is among the top priorities of the world health organization and
of the WHO/Mediterranean Zoonoses Control Program.
In Tunisia, where the disease is endemic and enzootic, the socio-economic
impact is very high. Indeed, Tunisia have experienced an increase in the
number of brucellosis cases. It was noticed that the incidence of the disease
was relatively low until 1988 (0.06%000). However, during the past ten
years (1989-1999), there has been a sharp increase of the infection in small
ruminants which raised intensively (60% ofsome livestock reared in south-
west of Tunisia were infected) and in human (incidence 4.6%000). Brucella
melitensis, biovar 3 was the only brucella species isolated.
But the situation has greatly improved since 1995, with decreasing in
human and animal incidence, thanks to large vaccination of livestock of
goats and sheeps, repeated annually. Human incidence decreased from
56.6%000 in 1993 to 8.3%000 in 1998 with a ratio vaccination coverage
of75% in small ruminants.
Animal vaccination should be reinforced by:
• reinforcement of epidemiologic surveillance with serological testing;
• implementation ofhygienic measures such as proper disposal ofaborted
materials, prevention of entry of new infection into the flack from neigh-
bouring countries, given attention to the hygienic conditions ofthe lambing
areas, forbidding the drink of fresh goat milk, the use of proper protective
clothing and adopting proper personal hygiene.
The experience and the results thus gained over the last few years will help
us to establish a national wide approach to limit and control the spread of
brucellosis among other livestock and consequently to reduce human cases.
IWeP3011 The importance of tetanus vaccination in
pregnants
S. Yegane Tosun', U. YenseI2, M. YiicetiirkJ
'M.S. Pediatric Hospital-Dep. ofCfin. Mic. and In! Dis, Manisa; 2Atatilrk
State Hospital-Obs. and Gynecology, Izmir; JHealth care center No 2 Manisa,
Turkey
Objectives: To investigate the tetanus immunization state in pregnants.
Methods: One hundred twenty one pregnants were investigated for detec-
tion of their tetanus seropositivity by micro EIA method (Sorin - Biome-
diea-Italy). Unvaccinated 52 and vaccinated 69 pregnants were included in
to the study. Vaccinated group had been vaccinated with tetanus vaccine at
present or in formerly pregnancies and unvaccinated group hadn't been
vaccinated in the last ten years.
Results: All of the vaccinated pregnants were found seropositive for tetanus
antibodies. Seven unvaccinated pregnants (13.5%) were found weakly
positive and 45 (86.5%) unvaccinated pregnants were found negative.
Condusion: In this study, it was pointed out that unvaccinated pregnants
were seronegative for tetanus antibodies; this statement is also important for
tetanus neonatorum. Therefore all pregnants should be vaccinated with
tetanus vaccine before or during pregnancy.
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IWeP30211mmunogenic activity of viral proteins in animals
infected with temperature sensitive mutant of herpes simplex
virus type-1 in mono- and polyvalent systems
A. TrzciDska, B. Litwmska,J. Siennicka, M. Kantoch
Dept. of Virology, Nationallnstytute of Hygiene, Warsaw, Poland
Objectives: To test the protein's immunogenic potency of temperature
sensitive mutant of herpes simplex virus type-l (ts HSV-l mutant).
Methods: Immunogenic activity ofproteins ofts HSV-I mutant was tested
by Western blot method in two systems: monovalent and polyvalent with
other attenuated virus strains (measles and mumps). The guinea pigs were
used as animal model. In monovalent system the immunogenic activity of
viral proteins in animals immunized with ts HSV-I mutant (lor II doses) was
studied and compared to results received for native HSV-I strain. In
polyvalent system the humoral response induced by antigens of ts HSV-I
mutant in the presence ofRNA virus strains was tested. Results obtained in
Western blot wcre densitometrically analysed.
Results: Results clearly indicated that althought simultaneous immuniza-
tion with 2 attenuated RNA viruses and ts HSV-I mutant had no effect on
IgG response to ts HSV-l mutant (antibodies titer measured by ELISA), but
some differences in immunogenic activity ofHSV proteins were observed.
In trivalent system of immunization response to only seven ts HSV-I
mutant's proteins were detected, while in monovalent system antibodies
to ten proteins of ts HSV-I mutant were observed. In all tested groups of
animals gB and gO were the most immunogenic viral proteins (100%
antibodies response to this proteins was observed).
Condusions: Simultaneous immunization with ts HSV-l mutant and RNA
attenuated virus strains (measles and mumps) had no effect on IgG response
to ts HSV-1 mutant, but differences could be observed on the level of
antigenic activity ofts HSV-l mutant's particular proteins.
IWeP303! A tim CH (chaperone/adhesin complex) vaccine for
cystitis
]. Roberts, M. Kaack1, G. Baskin!,]. Pinkner2, S. Hultgren2, S.
Palaszynski, S. Langermann3
I Tulane University, New Orleans, LA; 2Washington University, St. LOllis,
MO; 3Medimmune, Inc., Gaithmbllrg, MD, United Slates
Objective: Murine and primate studies have demonstrated that type I pilus
organelles, in particular their highly conserved FimH adhesin proteins, are
critic.1 for the establishment of Escherichia coli bladder infections. FimH
mediates attachment to mannosylated uroplakins of the bladder mucosa of
mice, cynomolgus monkeys and humans. A vaccine comprised of the FimH
adhesin complexed with its cognate chaperone FimC (FlinCH) has been
shown to reduce colonization by a variety ofuropathogenic E. coli isolates in
mice by > 99%. Furthermore, earlier challenge studies in cynomolgus
monkey with an E. coli cystitis isolate NU14 demonstrated complete
protection from bacteruria in vaccinated monkeys, which correlated with
lack of pyuria. We extend our findings to demonstrate protection against
infection by a highly invasive, pyelonephritic strain of E. coli OSI7 that
expresses both type I and P pili.
Methods: The monkeys were vaccinated (100 ug of imCH) and given
intraurethral challenge with 108 cfu/ml OSI7.
Results: Two of four monkeys were protected from bacteruria following
FimCH vaccination. The remaining two vaccinated monkeys, as well as 4/4
controls, had bacteriuria for three weeks; however, bacteriuria in immu-
nized monkeys was significantly lower than controls. All vaccinated
monkeys were protected against pyuria and showed no significant increase
in urine IL-8 levels. In contrast, all four control monkeys had significant
pyuria and hematuria, and showed increased urine IL-8.
Conclusion: These recent studies demonstrate that the FimCH vaccine is
effective in blocking E. coli attachment to the bladder epithelium and the
ensuing inflammatory responses by highly invasive pyelonephritic E. coli
strains.
[WeP304) Intradermal versus intramuscular administration of
a virosome formulated hepatitis Avaccine
p. Frosner l , G. Bastos l , M. Zellmeyer2, R. Gliick2, C. Herzog2
Max von Pettenkofer Institute, Munich, Germany; 2Swiss Serum & Vaccine
Instilute, Berne, Switzerland
Objectives: To compare immunogenicity and safety of two intradermal
(i.d.) regimens with the intramuscular (i.m.) administration of an alumi-
nium-free, virosome formulated hepatitis A vaccine (500 RIA units/0.5 mI).
Methods: 59 seronegative healthy adults (30 f, 29 m; 18-45 yrs) recieved
either 0.1 ml i.d. (Group A: l-site; 14 f, 16 m) orO.l ml + 0.1 mI (B: 2-site;
16 f, 13 m) of vaccine on day 1 and one booster dose of0.1 ml i.d. after 12
months. 61 adult controls received 0.5 ml vaccine i.m. (M: 30 f; 31 m; 18-45
yrs) on day I and at month 12. Safety was assessed for 4 days after
vaccinations. Serum ami-HAV antibodies were determined by EIA (ENZY-
MUN Boehringer) on days I, IS and 29, and at months 6, 12 and 13.
Results: The i.d. and i.m. administrations were well tolerated locally and
systemically. At 2 weeks 100% (A), 81% (B), and 100% (M) offemale and
94% (A), 85% (B), and 87% (M) ofmale subjects had titers of > 1= 10mlUI
ml. At 4 weeks all subjects but one male (A) had > 1=20 mlUIml, with
GMTs of75 (A), 136 (B) and 286 (M) mlUIml for female and 72 (A), 110 (B)
and 122 (M) mlUIml for male subjects. In Group A female and male subjects
reached on day 78, four weeks after a 2nd 0.1 ml i.d. dose, GMTs of151 and
101 mlU/ml. Female remained up to month 12at > 1=20m1U/ml, whereas
GMTs for males dropped in 19% (A), 17% (B), and 16% (M) to <20m1UI
ml at month 12. After boosting all subjects had titers of > 1=20 mlUIml,
with GMTsofl083 (A), 978 (B) and 3305 (M) mlU/ml for female and of428
(A), 620 (B) and %1 (M) mlU/ml for males.
Condusions: The virosome formulated hepatitis A vaccine is highly immu-
nogenic and well tolerated when given i.d.
IWeP30S1 Use of a virosome formulated hepatitis A vaccine in
adults> 50 years of age
V. D'Acremont l , B. Genton l , R. Gltick2, C. Herzog2
I Medical Outpatient Department, University Hospital, Lausanne; 2Swiss Serum
& Vaccine Institute, Berne, Switzerland
0bjectIyes: To evaluate the influence of age on the immune response to an
aluminum-free, virosome formulated hepatitis A vaccine (500 RIA units) in
adults.
Methods: In an open, uncontrolled study 77 unvaccinated adults> 50 yean
of age (Group A) were enrolled, as well as 65 control subjects aged 18-45
years. (B). After screening 29 seronegative subjects of Group A and 60
subjects ofGroup B remained in the study and received vaccine i.m. on day 1
and at month 12. Safety was assessed for 4 days after vaccinations. Serum
anti-HAV antibodies were determined by EIA (ENZYMUN Boehringer)
on days land 29, and at months 6, 12 and 13.
Results: Preliminary data are presented from this still ongo41g study. lu
expected, 100% seroprotection (> 1= 20 mlUIml) was achieved in Group B
at day 29 (GMT: 251 mlU/ml), in 86% at month 6 (63 mlU/ml) and in 91%
at month 12 (65 mlU/ml), with a strong antibody response to the booster
(GMT: 2020 mlU/ml or 31-fold increase). In Group A seroprotection was
achieved in 64% and 53% ofsubjects on day 29 (GMT: 52 mlUIml) and at
month 6 (GMT: 47 mlU/ml), respectively. Despite this lower primary
response a valid priming can be assumed as all 6 elderly subjects boosted so
far made a vigorous response to reach titers of782-16'384 mlU/ml (GMT:
2943 mIU/ml). Vaccination was well tolerated.
Conclusions: As expected, the primary immune response to a virosome
formulated hepatitis A vaccine is lower in the elderly as compared to young
adults. Nevertheless, elderly persons can be primed with a single dose and
seem to show a normal humoral immune response following boosting.
IWeP3061 Antibody kinetics following the primary and the
booster dose of a virosome formulated hepatitis A vaccine
F. Ambrosch l , R. Gltick2, C. Herzog2, A. Koren\, H. Kollaritseh l , G.
Wiedermann l
I Institute for Specific Prophylaxis & Trop. Med., University of Vienna,
Vienna, Australia; 2Swiss Serum & Vaccine Institute, Berne, Switzerland
Objectives: To determine onset and rate of the appearance of serum
antibodies after the priming dose with an aluminium-free, virosome
formulated hepatitis A vaccine (500 RIA units) and to evaluate the etrect
of a booster dose at month 12.
Methods: In an open, uncontro~ed study 2.1 seronegative adult volun~
(14 f, 13 m; 18-45 yrs) rec,eved 1.m. a pnmmg dose on day I and a booster
dose at month 12. Safety was assessed for 4 days after the immunisations.
Serum anti-HAY antibodies were determined by EIA (ENZYMUN Boeh-
Clinical Microbiology and Infection, Volume 6 Supplement 1, May 2000 239
ringer) on days 1, 3, 5, 7, 9,11,13,15,22 and 29, and at months 12,13,14,15,
16,17,18, and 24, respectively.
Results: Seroprotective antibody levels (> 1=20 mlU) were reached in
30% of subjects on day 11, in 81% on day 13, in 96.3% on day 15 and in
100% on day 22. GMTsforboth genders combined were 14,31, 100 and 242
mlUImI respectively. Female subjects reached seroprotection faster than
males, i.e. 93% vs 69% at day 13. As expected, GMTs were higher for
females, i.e. 36 vs27 mlU/ml on day 12 and 126 vs n mlU/mI on day 15. At
month 12 GMTs (both genders) were still high with 161 mlU/mI and
reached a peak of3n6 mlUIml after booster vaccination. At month 24 high
levels of 1175 rnJUIml persisted. Vaccination was well tolerated.
Conclusions: The aluminium-free, virosome formulated hepatitis A vaccine
is highly immunogenic. After a single dose protective levels of anti-HAV
antibodies develop in single individuals from day 9 onwards and by day 15
over 90% of individuals arc protected.
IWeP307! Subcutaneous versus intramuscular administration
of a virosome formulated hepatitis A vaccine
R. Steffen!, F. P. Lilcking', A. Ciurea!, R. GlUck2 , C. Het7og2
'Itlstitutefor Social & Preventive Mediline, University of Zurich, Zurich;
2Su,iss Serum & Vaccine Institute, Berne, Switzerland
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IWe091 Quantitative analysis of human cytomegalovirus DNA
in longitudinal samples of BAL fluid from lung transplant
recipients
Gerdt C. Riise l , Rune Andersson2, Tomas Bergstrom3, Folke N.
Nilsson4, Sigvard 010fsson3
Departments of'Respiratory Medicine; 2Infectious Diseases; JVirology;
4Cardiothoracic Surgery, Sahlgrenska University Hospital, Giiteborg, Sweden
Objectives: Cytomegalovirus (CMV)-infection is a common cause of
mortality and morbidity in transplant patients. In some sample material,
qualitative tests for CMV DNA may be too sensitive to discriminate
between patients with and without CMV disease. We investigated whether
a longitudinal quantification of CMV DNA in bronchoalveolar lavage
(BAL) fluid could be used to determine a viral load associated with disease in
lung transplant recipients.
Methods: CMV DNA levels in 340 BAL samples from 35 consecutive
lungtransplanted patients were analysed by the Vitral Quant Quantitative
CMV Detection Kit (BioSource Europe) during a median of 18 months.
Seventeen of the patients developed 27 episodes ofCMV disease.
Results: Patients with CMV disease had a significantly higher mean level of
CMV copies/mL BAL (1120 ± 4379) fluid compared to those without (180
± un, p < 0.01). Viral load as well as acute rejection were independent
risk factors associated with CMV disease, whereas HLA-DR matching and
bask immunosuppressive therapy were not. A diagnostic definition of
normality based upon the mean level of all the episodes without CMV
disease + 2 SD would discriminate only 9 of the 27 CMV episodes.
Conclusions: Although the viral load is increased during episodes ofclinical
CMV disease in lung transplant recipients, the quantitative PCR assessment
ofCMV DNA in BAL fluid is not specific enough as a diagnostic tool for
CMV disease. Other sample materials such as serum are currently investi-
gated quantitatively.
IWe010 IOKT3 treatment and lymphoma are possibly related
to the presence but not the amount of Epstein-Barr virus
genomes in serum in liver transplant recipients
L. Barkholt1•2, A. Linde3 , K. Falk3
'Dept. ofClinital Immunology; 2Dept. of Transplantation Surgery; JSwedish
ItutitutefoT Infectious Disease Control, Karo/inska Institutet, Stockholm,
Sweden
Objectives: To compare immunogenicity and safety of the subcutaneous
(s.c.) versus the intramuscular (i.m.) administration of an aluminium-free,
virosome formulated hepatitis A vaccine (500 RIA units) in healthy adult
volunteers.
Methods: In an open, uncontrolled gender stratified study 113 adults, aged
18-45 years, were enrolled. 44 seronegative volunteers (Group A: 23 f, 21 m)
received 0.5 ml ofhepatitis A vaccine s.c. and a control group of69 adults (B:
33 f, 36 m) i.m. on day 1 and at month 12. Safety was assessed for 4 days after
the immunisations. Serum anti-HAV antibodies were determined by EtA
(ENZYMUN Boehringer) at baseline, on day 29, and at months 6,12 and
13.
Results: Seroprotective antibody levels of > 1=20 mlUIrnJ were attained
on day 29 by 95.5% and 95.6'Yo, at month 6 by 91 % and 90%, and at month
12 by 93% and %% ofsubjeers in groups A and B, respectively. GMTs were
lower for Group A at all time points, but still 68 mlUIml vs 89 mlUIrnJ at
month 12. Strong booster responses were recorded for groups A (938 mlUI
ml or 14-fold rise) and B (2368 rnJU/ml or 27-fold rise). GMTs for female
subjects were generally higher, except for the booster response in group A
(877 vs 1014 mIU/rnJ). Vaccination was well tolerated.
Conclusions: With the aluminium-fn:e, virosome formulated hepatitis A
vaccine the s.c. administration can be chosen depending on the need of the
subject to be vaccinated without the risk ofsubcutaneous nodules. Seropro-
tective titers are reached within 1 month for both routes and are still present
in > 90% at month 12.
Objective: We sought to determine factors affecting the Epstein-Barr virus
(EBV) genome load in serum after liver transplantation (LTX).
Material & Methods: Real-time PCR on serum was used after extraction
ofDNA by Qaigen for measurement ofthe EBV genome load. Consecutive
serum samples obtained from 21 LTX patients preLTX and within the 6nt
year were examined. Steroid resistant acute rejections were treated with
OKT3 in 4/11 cyclosporin A (CsA) and 3/10 tacrolimus treated patients.
Results: EBV DNA was found in 5111 CsA and 6/10 tacrolimus treated
patients. It was demonstrated in 6 of7 patients with OKT3 therapy (3 CsA
and 3 tacrolimus cases). There was no difference in median EBV DNA copy
number in patients with CsA or tacrolimus (310/ml vs. 380/rnJ), or with or
without OKT3 treatment (380/ml vs. 370/ml). EBV genomes were not
found at the end ofacyclovir or ganciclovir therapy but was detected 1 to 14
weeks later in 4 of 6 cases. One patient developed EBV lymphoma and
another one EBV hepatitis 13 months and 24 days postLTX, respectively.
Both patienrs had received OKT3. EBV genome was found in their serum
samples. but the load was not significantly different from what was found in
other patients.
Conclusion: EBV in serum is a possible marker of an active infection.
OKT3-treatment seems to be of greatest importance for its appearance.
EBV DNA in serum might be a marker for EBV lymphoma, but in this
srudy viral load was not different in patients with lymphoma as compared
with other patients.
IWe011! Candida glabrata fungemia in immunocornpromised
cancer patients: Epidemiology and outcome analysis
M. Mardani, H. Hanna,]. Abbas, A. Alrahwan, R. Hachem, I. Raad
Univ. of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Between January 1993 and May 1998, we identified % immunocompro-
rnised cancer patients (pts) with Candida glabrata fungemia. With the wide-
spread use offluconazole prophylaxis after 1992 at our center, the incidence
of C. glabrata fungemia increased. Most immunocompromised cancer pts
"';th C. glabrata fungemia were neutropenic (47%). The underlying disease
was leukemia (47%), solid tumor (38%), and lymphoma (15%). Most (64%)
of these pts with C. glabrata fungemia received fluconazole prophylaxis prior
to the onset of fungemia. Disseminated infection occurred in 37 pts (39%),
while 15% of all C. glabrata fungemia infections were catheter-related.
Breakthrough candidemia on amphotencin B or liposomal compound
regimen occurred in 10 pts, 5 of whom had disseminated infection. C.
glabrata fungemia was the primary cause ofdeath in 13 pts (14%), and was a
contributing factor to death in 29 other prs (39%). In conclusion, C.glabrata
fungernia in immunocompromised cancer pts is associated with high
frequency of dissemination and mortality. This infection should be con-
